

# **Product datasheet for TL310169V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

# **Prolactin Receptor (PRLR) Human shRNA Lentiviral Particle (Locus ID 5618)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Prolactin Receptor (PRLR) Human shRNA Lentiviral Particle (Locus ID 5618)

Locus ID: 5618

Synonyms: HPRL; hPRLrl; MFAB; RI-PRLR Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** PRLR - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000949, NM 001204314, NM 001204315, NM 001204316, NM 001204317,

NM 001204318, NR 037910, NM 000949.1, NM 000949.2, NM 000949.3, NM 000949.4, NM 000949.5, NM 000949.6, NM 001204318.1, NM 001204317.1, NM 001204315.1,

NM 001204316.1, NM 001204314.1, NM 001204314.2, BC059392, BC059392.1, NM 000949.7

UniProt ID: P16471

**Summary:** This gene encodes a receptor for the anterior pituitary hormone, prolactin, and belongs to

the type I cytokine receptor family. Prolactin-dependent signaling occurs as the result of ligand-induced dimerization of the prolactin receptor. Several alternatively spliced transcript variants encoding different membrane-bound and soluble isoforms have been described for this gene, which may function to modulate the endocrine and autocrine effects of prolactin in

normal tissue and cancer. [provided by RefSeq, Feb 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





### Prolactin Receptor (PRLR) Human shRNA Lentiviral Particle (Locus ID 5618) - TL310169V

## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).